8-K Announcements
6Material company update
Apr 29, 2026·SEC
Material company update
Mar 17, 2026·SEC
Material company update
Feb 27, 2026·SEC
GE HealthCare Technologies Inc.(GEHC)Earnings, Financials & Key Ratios
GEHC•NASDAQ
$61.74
$28.08B mkt cap·13.6× P/E·Price updated May 6, 2026
AboutGE HealthCare Technologies Inc. engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, Europe, the Middle East, Africa, China, Taiwan, Mongolia, Hong Kong, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging segment offers molecular imaging, computed tomography (CT) scanning, magnetic resonance (MR) imaging, image-guided therapy, and X-ray systems, as well as women's health products. The Ultrasound segment provides screening, diagnosis, treatment, and monitoring of certain diseases through radiology and primary care, women's health, cardiovascular, and point of care and handheld ultrasound solutions, as well as surgical visualization and guidance products. The Patient Care Solutions segment involved in the provision of medical devices, consumable products, services, and digital solutions through patient monitoring, anesthesia delivery and respiratory care, diagnostic cardiology, and maternal infant care products. The Pharmaceutical Diagnostics supplies diagnostic agents, including CT, angiography and X-ray, MR, single-photon emission computed tomography, positron emission tomography, and ultrasound to the radiology and nuclear medicine industry. The segment also provides contrast media pharmaceuticals, administered to a patient prior to certain diagnostic scans to increase the visibility of tissues or structures during imaging exams; and molecular imaging agents, or radiopharmaceuticals, which are molecular tracers labeled with radioisotopes that are injected into a patient prior to a diagnostic imaging scan. The company was incorporated in 2022 and is headquartered in Chicago, Illinois.Show more
- Revenue$20.63B+4.8%
- EBITDA$3.34B+4.2%
- Net Income$2.08B+4.6%
- EPS (Diluted)4.55+4.8%
- Gross Margin39.99%-4.1%
- EBITDA Margin16.19%-0.6%
- Operating Margin13.39%+0.4%
- Net Margin10.1%-0.3%
- ROE21.65%-13.3%
- ROIC13.27%+0.4%
- Debt/Equity0.94-12.9%
- Interest Coverage7.13+16.6%
GEHC Key Insights
GE HealthCare Technologies Inc. (GEHC) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Excellent 3Y average ROE of 21.7%
- ✓Healthy 5Y average net margin of 10.3%
✗Weaknesses
- ✗Profits declining 31.5% over 5 years
- ✗Weak momentum: RS Rating 16 (bottom 16%)
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
GEHC Price & Volume
GE HealthCare Technologies Inc. (GEHC) stock price & volume — 10-year historical chart
Loading chart...
GEHC Growth Metrics
GE HealthCare Technologies Inc. (GEHC) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years3.74%
3 Years3.99%
TTM0.79%
Profit CAGR
10 Years-
5 Years-31.53%
3 Years2.84%
TTM-31.06%
EPS CAGR
10 Years-
5 Years0.63%
3 Years2.54%
TTM-31.16%
Return on Capital
10 Years12.68%
5 Years12.14%
3 Years11.01%
Last Year10.76%
GEHC Recent Earnings
GE HealthCare Technologies Inc. (GEHC) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 10/12 qtrs (83%)●Beat Revenue 8/12 qtrs (67%)
Q2 2026Latest
Apr 29, 2026EPS
$0.99
Est $1.07
-7.5%
Revenue
$5.1B
Est $5.0B
+1.8%
Q1 2026
Feb 4, 2026EPS
$1.44
Est $1.40
+2.9%
Revenue
$5.7B
Est $5.6B
+1.5%
Q4 2025
Oct 29, 2025EPS
$1.07
Est $1.05
+1.9%
Revenue
$5.1B
Est $5.1B
+1.1%
Q3 2025
Jul 30, 2025EPS
$1.06
Est $0.92
+15.5%
Revenue
$5.0B
Est $5.0B
+0.7%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Apr 29, 2026 | $0.99vs $1.07-7.5% | $5.1Bvs $5.0B+1.8% |
| Q1 2026 | Feb 4, 2026 | $1.44vs $1.40+2.9% | $5.7Bvs $5.6B+1.5% |
| Q4 2025 | Oct 29, 2025 | $1.07vs $1.05+1.9% | $5.1Bvs $5.1B+1.1% |
| Q3 2025 | Jul 30, 2025 | $1.06vs $0.92+15.5% | $5.0Bvs $5.0B+0.7% |
Based on last 12 quarters of dataView full earnings history →
GEHC Peer Comparison
GE HealthCare Technologies Inc. (GEHC) competitors in Healthcare Data, Analytics and AI — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 SYK | 111.96B | 292.33 | 34.80 | 11.16% | 12.92% | 15.04% | 0.66 | |
 BSX | 83.23B | 56.00 | 28.87 | 19.87% | 14.4% | 12.4% | 0.51 | |
 EW | 47.97B | 83.20 | 45.46 | 11.55% | 17.64% | 10.35% | 0.07 | |
 PHG | 25.9B | 27.23 | 24.95 | -1.04% | 5.02% | 8.19% | 0.74 | |
 HOLX | 16.97B | 76.01 | 30.53 | 1.74% | 13.18% | 10.37% | 0.52 | |
 MDT | 99.48B | 77.60 | 21.50 | 3.62% | 13% | 9.45% | 0.59 | |
 ABT | 149.97B | 86.25 | 11.29 | 4.59% | 31.88% | 27.26% | 0.32 | |
 BAX | 8.77B | 16.98 | -9.70 | 5.72% | -9.7% | -16.5% | 1.64 |
Compare GEHC vs Peers
GE HealthCare Technologies Inc. (GEHC) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
GEHC Income Statement
GE HealthCare Technologies Inc. (GEHC) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|
| Sales/Revenue | 17.16B | 17.59B | 18.34B | 19.55B | 19.67B | 20.63B | 19.95B |
| Revenue Growth % | - | 2.45% | 4.3% | 6.6% | 0.61% | 4.84% | 0.79% |
| Cost of Goods Sold | 10.4B | 10.41B | 11.16B | 11.63B | 11.47B | 12.38B | 11.46B |
| COGS % of Revenue | 60.57% | 59.2% | 60.86% | 59.48% | 58.29% | 60.01% | - |
| Gross Profit | 6.77B▲ 0% | 7.17B▲ 6.0% | 7.18B▲ 0.1% | 7.92B▲ 10.3% | 8.21B▲ 3.6% | 8.25B▲ 0.5% | 8.49B▲ 0% |
| Gross Margin % | 39.43% | 40.8% | 39.14% | 40.52% | 41.71% | 39.99% | 42.55% |
| Gross Profit Growth % | - | 6.01% | 0.07% | 10.35% | 3.57% | 0.51% | - |
| Operating Expenses | 4.05B | 4.38B | 4.66B | 5.49B | 5.58B | 5.49B | 6B |
| OpEx % of Revenue | 23.58% | 24.9% | 25.39% | 28.06% | 28.37% | 26.59% | - |
| Selling, General & Admin | 3.24B | 3.56B | 3.63B | 4.28B | 4.27B | 4.22B | 4.23B |
| SG&A % of Revenue | 18.86% | 20.26% | 19.8% | 21.9% | 21.7% | 20.48% | - |
| Research & Development | 810M | 816M | 1.03B | 1.21B | 1.31B | 1.26B | 1.3B |
| R&D % of Revenue | 4.72% | 4.64% | 5.59% | 6.16% | 6.66% | 6.11% | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | 2.72B▲ 0% | 2.79B▲ 2.8% | 2.52B▼ 9.8% | 2.44B▼ 3.4% | 2.63B▲ 7.8% | 2.76B▲ 5.2% | 2.49B▲ 0% |
| Operating Margin % | 15.85% | 15.89% | 13.75% | 12.45% | 13.34% | 13.39% | 12.46% |
| Operating Income Growth % | - | 2.76% | -9.77% | -3.45% | 7.8% | 5.22% | - |
| EBITDA | 3.35B | 3.42B | 3.15B | 3.04B | 3.21B | 3.34B | 3.35B |
| EBITDA Margin % | 19.52% | 19.45% | 17.2% | 15.57% | 16.29% | 16.19% | 16.76% |
| EBITDA Growth % | - | 2.09% | -7.75% | -3.49% | 5.25% | 4.21% | 1.92% |
| D&A (Non-Cash Add-back) | 630M | 625M | 633M | 610M | 580M | 578M | 844M |
| EBIT | 2.78B | 2.92B | 2.53B | 2.9B | 3.09B | 3.21B | 2.33B |
| Net Interest Income | -17M | -6M | -86M | -516M | -505M | -450M | -435M |
| Interest Income | 49M | 34M | 0 | 26M | 0 | 0 | 0 |
| Interest Expense | 66M | 40M | 86M | 542M | 505M | 450M | 435M |
| Other Income/Expense | -10M | 80M | -10M | -74M | -44M | 6M | -523M |
| Pretax Income | 2.71B▲ 0% | 2.88B▲ 6.1% | 2.51B▼ 12.6% | 2.36B▼ 6.0% | 2.58B▲ 9.3% | 2.77B▲ 7.2% | 1.96B▲ 0% |
| Pretax Margin % | 15.79% | 16.35% | 13.7% | 12.08% | 13.12% | 13.42% | 9.84% |
| Income Tax | 652M | 600M | 563M | 743M | 531M | 614M | 440M |
| Effective Tax Rate % | 24.06% | 20.87% | 22.41% | 31.47% | 20.57% | 22.18% | 22.41% |
| Net Income | 13.85B▲ 0% | 2.25B▼ 83.8% | 1.92B▼ 14.7% | 1.57B▼ 18.2% | 1.99B▲ 27.1% | 2.08B▲ 4.6% | 1.5B▲ 0% |
| Net Margin % | 80.67% | 12.78% | 10.45% | 8.02% | 10.13% | 10.1% | 7.54% |
| Net Income Growth % | - | -83.77% | -14.73% | -18.16% | 27.1% | 4.57% | -31.06% |
| Net Income (Continuing) | 2.06B | 2.27B | 1.95B | 1.62B | 2.05B | 2.15B | 1.52B |
| Discontinued Operations | 11.84B | 18M | 18M | -4M | 0 | 0 | 0 |
| Minority Interest | 247M | 241M | 235M | 177M | 206M | 220M | 230M |
| EPS (Diluted) | 4.41▲ 0% | 4.90▲ 11.1% | 4.22▼ 13.9% | 3.02▼ 28.4% | 4.34▲ 43.7% | 4.55▲ 4.8% | 3.29▲ 0% |
| EPS Growth % | - | 11.11% | -13.88% | -28.44% | 43.71% | 4.84% | -31.16% |
| EPS (Basic) | 4.41 | 4.90 | 4.22 | 3.04 | 4.37 | 4.56 | - |
| Diluted Shares Outstanding | 454.71M | 454.71M | 453.93M | 458M | 459M | 460.27M | 457M |
| Basic Shares Outstanding | 454.71M | 454.71M | 453.93M | 455M | 456M | 456.52M | 456M |
| Dividend Payout Ratio | - | - | - | 2.61% | 2.76% | 3.07% | - |
GEHC Balance Sheet
GE HealthCare Technologies Inc. (GEHC) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|
| Total Current Assets | 5.45B | 6.54B | 7.82B | 9.01B | 9.52B | 10.7B | 9.98B |
| Cash & Short-Term Investments | 1.01B | 556M | 1.45B | 2.5B | 2.89B | 4.51B | 2.29B |
| Cash Only | 1.01B | 556M | 1.45B | 2.5B | 2.89B | 4.51B | 2.29B |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 2.66B | 3.79B | 3.99B | 4.32B | 4.38B | 3.96B | 4.74B |
| Days Sales Outstanding | 56.5 | 78.69 | 79.46 | 80.55 | 81.19 | 69.99 | 81.63 |
| Inventory | 1.59B | 1.95B | 2.15B | 1.96B | 1.94B | 2.23B | 2.35B |
| Days Inventory Outstanding | 55.96 | 68.22 | 70.47 | 61.51 | 61.72 | 65.88 | 73.02 |
| Other Current Assets | 190M | 250M | 226M | 231M | 311M | 0 | 605M |
| Total Non-Current Assets | 18.78B | 19.77B | 19.72B | 23.44B | 23.57B | 22.2B | 27.14B |
| Property, Plant & Equipment | 2.2B | 2.23B | 2.31B | 2.5B | 2.55B | 3.09B | 3.1B |
| Fixed Asset Turnover | 7.79x | 7.87x | 7.93x | 7.82x | 7.71x | 6.67x | 6.56x |
| Goodwill | 11.87B | 12.89B | 12.81B | 12.94B | 13.14B | 13.49B | 15.06B |
| Intangible Assets | 1.6B | 1.85B | 1.52B | 1.25B | 1.08B | 1.13B | 1.91B |
| Long-Term Investments | 709M | 665M | 663M | 733M | 804M | 0 | 1.95B |
| Other Non-Current Assets | 909M | 839M | 860M | 1.55B | 1.53B | 0 | 5.36B |
| Total Assets | 24.23B▲ 0% | 26.31B▲ 8.6% | 27.54B▲ 4.7% | 32.45B▲ 17.8% | 33.09B▲ 2.0% | 36.91B▲ 11.5% | 37.13B▲ 0% |
| Asset Turnover | 0.71x | 0.67x | 0.67x | 0.60x | 0.59x | 0.56x | 0.55x |
| Asset Growth % | - | 8.59% | 4.68% | 17.85% | 1.96% | 11.54% | 40.24% |
| Total Current Liabilities | 6.52B | 6.76B | 7.19B | 8.98B | 9.55B | 9.11B | 8.53B |
| Accounts Payable | 2.39B | 2.73B | 3.09B | 2.95B | 3.02B | 3.25B | 3.41B |
| Days Payables Outstanding | 83.8 | 95.68 | 101.04 | 92.49 | 96.19 | 95.84 | 100.47 |
| Short-Term Debt | 132M | 110M | 119M | 1.12B | 1.5B | 508M | 139M |
| Deferred Revenue (Current) | 1.81B | 1.86B | 1.9B | 1.92B | 1.94B | 0 | 6.13B |
| Other Current Liabilities | 1.27B | 1.17B | 1.23B | 1.48B | 1.45B | 5.35B | 1.41B |
| Current Ratio | 0.84x | 0.97x | 1.09x | 1.00x | 1.00x | 1.18x | 1.18x |
| Quick Ratio | 0.59x | 0.68x | 0.79x | 0.78x | 0.79x | 0.93x | 0.93x |
| Cash Conversion Cycle | 28.66 | 51.24 | 48.89 | 49.58 | 46.72 | 40.03 | 54.18 |
| Total Non-Current Liabilities | 2.73B | 2.65B | 10.76B | 16.16B | 14.88B | 17.2B | 17.7B |
| Long-Term Debt | 31M | 31M | 8.23B | 8.44B | 7.45B | 9.49B | 10.13B |
| Capital Lease Obligations | 305M | 296M | 282M | 311M | 310M | 0 | 953M |
| Deferred Tax Liabilities | 459M | 385M | 370M | 68M | 56M | 193M | 793M |
| Other Non-Current Liabilities | 1.37B | 1.31B | 1.24B | 6.64B | 6.38B | 7.51B | 26.28B |
| Total Liabilities | 9.25B | 9.41B | 17.95B | 25.14B | 24.44B | 26.31B | 26.23B |
| Total Debt | 468M | 437M | 8.63B | 9.86B | 9.38B | 10B | 10.58B |
| Net Debt | -539M | -119M | 7.19B | 7.36B | 6.49B | 5.49B | 8.29B |
| Debt / Equity | 0.03x | 0.03x | 0.90x | 1.35x | 1.08x | 0.94x | 0.94x |
| Debt / EBITDA | 0.14x | 0.13x | 2.74x | 3.24x | 2.93x | 2.99x | 3.16x |
| Net Debt / EBITDA | -0.16x | -0.03x | 2.28x | 2.42x | 2.02x | 1.64x | 1.64x |
| Interest Coverage | 42.06x | 72.88x | 29.44x | 5.36x | 6.11x | 7.13x | 5.35x |
| Total Equity | 14.97B▲ 0% | 16.9B▲ 12.8% | 9.59B▼ 43.2% | 7.31B▼ 23.8% | 8.65B▲ 18.4% | 10.6B▲ 22.5% | 10.9B▲ 0% |
| Equity Growth % | - | 12.84% | -43.23% | -23.79% | 18.37% | 22.49% | 82.78% |
| Book Value per Share | 32.93 | 37.16 | 21.13 | 15.96 | 18.85 | 23.03 | 23.85 |
| Total Shareholders' Equity | 14.73B | 16.66B | 9.36B | 7.13B | 8.45B | 10.38B | 10.67B |
| Common Stock | 0 | 0 | 0 | 5M | 5M | 5M | 5M |
| Retained Earnings | 0 | 0 | 0 | 1.33B | 3.26B | 5.28B | 5.65B |
| Treasury Stock | 0 | 0 | 0 | 0 | -25M | -225M | -325M |
| Accumulated OCI | 14.73B | 16.66B | 9.36B | -691M | -1.38B | -1.39B | -1.4B |
| Minority Interest | 247M | 241M | 235M | 177M | 206M | 220M | 230M |
GEHC Cash Flow Statement
GE HealthCare Technologies Inc. (GEHC) cash flow — operating, investing & free cash flow history
| Line item | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|
| Cash from Operations | 1.69B | 1.61B | 2.11B | 2.1B | 1.95B | 1.99B | 1.99B |
| Operating CF Margin % | 9.83% | 9.14% | 11.52% | 10.75% | 9.92% | 9.64% | - |
| Operating CF Growth % | - | -4.74% | 31.49% | -0.57% | -7.14% | 1.9% | 190.46% |
| Net Income | 2.06B | 2.27B | 1.95B | 1.62B | 2.05B | 2.15B | 1.5B |
| Depreciation & Amortization | 630M | 625M | 633M | 610M | 580M | 578M | 449M |
| Stock-Based Compensation | 0 | 76M | 67M | 114M | 125M | 130M | 107M |
| Deferred Taxes | 652M | 600M | 563M | 743M | 531M | 0 | 510M |
| Other Non-Cash Items | -1.6B | -599M | -806M | -1.01B | -1.28B | -517M | -755M |
| Working Capital Changes | -52M | -1.37B | -293M | 22M | -59M | -357M | -247M |
| Change in Receivables | -257M | -1.16B | -440M | -171M | -150M | -216M | -319M |
| Change in Inventory | 100M | -435M | -402M | 111M | -81M | -142M | -159M |
| Change in Payables | -113M | 263M | 481M | -13M | 126M | 90M | 165M |
| Cash from Investing | 19.99B | -1.76B | -398M | -558M | -914M | -1.05B | -3.14B |
| Capital Expenditures | -237M | -248M | -310M | -387M | -401M | -482M | -508M |
| CapEx % of Revenue | 1.38% | 1.41% | 1.69% | 1.98% | 2.04% | 2.34% | - |
| Acquisitions | -78M | -1.48B | 0 | -147M | -313M | 0 | -109M |
| Investments | - | - | - | - | - | - | - |
| Other Investing | 20.3B | -32M | -29M | 24M | -160M | -447M | -2.41B |
| Cash from Financing | -21.54B | -263M | -822M | -478M | -573M | 617M | 924M |
| Debt Issued (Net) | -16M | -12M | 8.2B | 1.14B | -423M | 967M | 1.37B |
| Equity Issued (Net) | 0 | 0 | 0 | 0 | 33M | -163M | -178M |
| Dividends Paid | 0 | 0 | 0 | -41M | -55M | -64M | -64M |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | -200M | -200M |
| Other Financing | -21.53B | -251M | -9.03B | -1.58B | -128M | -123M | -205M |
| Net Change in Cash | 143M▲ 0% | -451M▼ 415.4% | 890M▲ 297.3% | 1.05B▲ 18.5% | 387M▼ 63.3% | 1.62B▲ 319.1% | -188M▲ 0% |
| Free Cash Flow | 1.43B▲ 0% | 1.36B▼ 4.8% | 1.8B▲ 32.7% | 1.71B▼ 4.9% | 1.55B▼ 9.6% | 1.51B▼ 2.8% | 1.52B▲ 0% |
| FCF Margin % | 8.32% | 7.73% | 9.83% | 8.77% | 7.88% | 7.3% | 7.62% |
| FCF Growth % | - | -4.83% | 32.67% | -4.94% | -9.57% | -2.84% | 10.63% |
| FCF per Share | 3.14 | 2.99 | 3.97 | 3.74 | 3.38 | 3.27 | 3.27 |
| FCF Conversion (FCF/Net Income) | 0.12x | 0.72x | 1.10x | 1.34x | 0.98x | 0.95x | 1.01x |
| Interest Paid | 46M | 21M | 0 | 570M | 550M | 0 | 249M |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
GEHC Key Ratios
GE HealthCare Technologies Inc. (GEHC) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|
| Return on Equity (ROE) | 14.1% | 14.47% | 18.55% | 24.97% | 21.65% | 14.45% |
| Return on Invested Capital (ROIC) | 13.43% | 11.27% | 11.61% | 13.21% | 13.27% | 13.27% |
| Gross Margin | 40.8% | 39.14% | 40.52% | 41.71% | 39.99% | 42.55% |
| Net Margin | 12.78% | 10.45% | 8.02% | 10.13% | 10.1% | 7.54% |
| Debt / Equity | 0.03x | 0.90x | 1.35x | 1.08x | 0.94x | 0.94x |
| Interest Coverage | 72.88x | 29.44x | 5.36x | 6.11x | 7.13x | 5.35x |
| FCF Conversion | 0.72x | 1.10x | 1.34x | 0.98x | 0.95x | 1.01x |
| Revenue Growth | 2.45% | 4.3% | 6.6% | 0.61% | 4.84% | 0.79% |
GEHC SEC Filings & Documents
GE HealthCare Technologies Inc. (GEHC) SEC filings — annual & quarterly reports (10-K, 10-Q)
GEHC Frequently Asked Questions
GE HealthCare Technologies Inc. (GEHC) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
GE HealthCare Technologies Inc. (GEHC) reported $19.95B in revenue for fiscal year 2025. This represents a 16% increase from $17.16B in 2020.
GE HealthCare Technologies Inc. (GEHC) grew revenue by 4.8% over the past year. Growth has been modest.
Yes, GE HealthCare Technologies Inc. (GEHC) is profitable, generating $1.50B in net income for fiscal year 2025 (10.1% net margin).
Dividend & Returns
Yes, GE HealthCare Technologies Inc. (GEHC) pays a dividend with a yield of 0.23%. This makes it attractive for income-focused investors.
GE HealthCare Technologies Inc. (GEHC) has a return on equity (ROE) of 21.6%. This is excellent, indicating efficient use of shareholder capital.
GE HealthCare Technologies Inc. (GEHC) generated $1.52B in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
Explore More GEHC
GE HealthCare Technologies Inc. (GEHC) financial analysis — history, returns, DCA and operating performance tools
Full GEHC Stock Analysis
Analyst verdict, bull/bear case, risk factors and peer comparison
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates